Share on StockTwits

Questcor Pharmaceuticals (NASDAQ:QCOR) was downgraded by Oppenheimer from an “outperform” rating to a “market perform” rating in a research note issued on Friday, TheFlyOnTheWall.com reports. They currently have a $86.00 target price on the stock. Oppenheimer’s target price would suggest a potential downside of 9.38% from the stock’s previous close.

A number of other firms have also recently commented on QCOR. Analysts at Zacks downgraded shares of Questcor Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Tuesday, July 1st. They now have a $97.00 price target on the stock. Separately, analysts at Mizuho downgraded shares of Questcor Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, May 19th. They now have a $92.00 price target on the stock. Finally, analysts at Piper Jaffray downgraded shares of Questcor Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday, May 12th. They now have a $98.00 price target on the stock, up previously from $96.00. Eight analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $86.20.

Shares of Questcor Pharmaceuticals (NASDAQ:QCOR) opened at 94.90 on Friday. Questcor Pharmaceuticals has a one year low of $47.71 and a one year high of $97.80. The stock’s 50-day moving average is $92.56 and its 200-day moving average is $77.88. The company has a market cap of $5.612 billion and a price-to-earnings ratio of 18.30.

Questcor Pharmaceuticals (NASDAQ:QCOR) last announced its earnings results on Thursday, July 24th. The company reported $1.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.74 by $0.11. The company had revenue of $278.80 million for the quarter, compared to the consensus estimate of $261.02 million. During the same quarter in the previous year, the company posted $1.12 earnings per share. The company’s revenue for the quarter was up 38.5% on a year-over-year basis. On average, analysts predict that Questcor Pharmaceuticals will post $6.97 earnings per share for the current fiscal year.

In other Questcor Pharmaceuticals news, Insider Don M. Bailey unloaded 40,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $95.54, for a total transaction of $3,821,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.